The stock's fall snapped a two-day winning streak.

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

CASEY -- Two area boys and girls track teams competed at the Casey-Westfield home meet Monday. Cumberland and Windsor/Stewardson-Srasburg had several athletes finish well. Dieterich had one runner ...

This was the stock's second consecutive day of gains.

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report released on Wednesday morning, Ratings reports. The brokerage issued an outperform ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Rocket Pharmaceuticals (NasdaqGM:RCKT) with a ...

About Entos Pharmaceuticals Inc. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and re-dosable nucleic acid delivery technologies.